We prepared a legal analysis for Antegenes, a provider of novel genetic tests designed to assess personal cancer risks. The analysis explored the possibilities of Antegenes to expand to other countries.

Expansion in mind

For example, the health startup was facing the question if and on what conditions other European Union member states can limit the use of genetic tests across national borders. We also analysed issues regarding protection of personal data. Today, Antigenes has already expanded to the UK market.

Antegenes participated in our Shared Mission program, which provides EUR 100,000 worth of free legal advice to companies and initiatives that aim to do good in local and global communities in an innovative way.


Antegenes is an innovation-oriented Estonian medical technology company founded in 2018. It was the first company in the country to start using genetic tests to assess personal cancer risks. The company’s mission is to enable people to have a better, healthier, and longer life by helping individuals, healthcare professionals, and organisations use genetic information for personal and public health.

Our client team

Antegenes was advised by our partner Mihkel Miidla, senior associate Lise-Lotte Lääne and associate Liisa Kuuskmaa.